SCHEMBL16398799

SCHEMBL16398799

Cc1sc(-c2cccc(C(F)(F)F)n2)nc1-c1nn[nH]c1C#N

nearest known ligand 0.36

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ TGFBR1 P36897 3/20 0.33
▸ NOTUM Q6P988 1/20 0.33
▸ IDH1 O75874 10/20 0.33
▸ IDH2 P48735 4/20 0.33
▸ PIM1 P11309 1/20 0.32
▸ PIM3 Q86V86 1/20 0.32
▸ PIM2 Q9P1W9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18005108 0.87 TGFBR1 (0.32) TGFBR1NOTUMIDH1IDH2PIM1
SCHEMBL18005092 0.83 IDH1 (0.33) IDH1IDH2
SCHEMBL18005109 0.80 USP30 (0.35) TGFBR1NOTUMIDH1IDH2PIM1
SCHEMBL18005081 0.80 TRPV3 (0.34) —
SCHEMBL16398564 0.80 ALDH1A1 (0.40) —
SCHEMBL16399924 0.80 ALDH1A1 (0.44) PIM1PIM3
SCHEMBL16399216 0.79 NPC1 (0.42) —
SCHEMBL18004674 0.78 TGFBR1 (0.39) TGFBR1NOTUMIDH1IDH2PIM1
SCHEMBL18004595 0.78 SYK (0.37) NOTUMIDH1IDH2
SCHEMBL18004615 0.76 CTSS (0.43) TGFBR1NOTUMIDH1PIM1PIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 — — EP disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
EP-3022199-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2016-05-25 — — EP disclosed
US-9067885-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2015-06-30 — — US disclosed
WO-2015008872-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 TGFBR1 2745/4885NOTUM 1379/4885IDH1 55/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 TGFBR1 2745/4885NOTUM 1379/4885IDH1 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback